Pharma Industry Reputation: What Is At Stake With COVID-19?
Executive Summary
The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.
You may also be interested in...
Can Pharma Rebuild Its Reputation? COVID-19 Means A Big Responsibility, And Opportunity
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
Kodak Deal On Hold Until Allegations Cleared
A major $765m loan agreed by the US International Development Finance Corporation to allow Kodak to establish a pharmaceuticals unit has been put on hold until allegations of wrongdoing are resolved, as rumors swirl about insider trading.
Instilling Public Trust in COVID Vaccine Allocation Plan: Gov’t Hopes Outside Scientists Will Help
National Academy of Medicines is developing a framework for equitable COVID-19 vaccine distribution which, CDC and NIH hope, will help shore up public trust ahead of the unenviable task of having to decide who should be the first to get limited vaccine resources. CDC Director Robert Redfield said the distribution strategy should help lessen the health disparities seen with COVID-19 infections.
Need a specific report? 1000+ reports available
Buy Reports